24 studies on Survodutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 137 published Survodutide COA source records from third-party laboratories, covering 58 publicly attributable vendor identities. Across 121 records with positive numeric purity, the arithmetic mean is 99.53%. 0 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 0 positive purity results are below 90%; 5 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-13. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-18, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 10 mg | $31.50 | $31.50–$31.50 | $3.15 | 1 source · 1 offer |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-13. Aggregate calculated: 2026-10-18T04:26:38.470604+00:00. Calculation time is not a laboratory observation date.
Within that total, 24 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 13 | 99.34% | 0 of 12 (0.0%) 0 0% / not detected · 0 wrong compound · 1 unclassified | Reveal with Pro → | |
| #2 | 7 | 99.58% | 0 of 6 (0.0%) 0 0% / not detected · 0 wrong compound · 1 unclassified | Reveal with Pro → | |
| #3 | 4 | 99.77% | 0 of 4 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #119125 (99.93%) · #111500 (99.91%) · #110506 (99.76%) · #117973 · #99865 (99.8%) · #94666 (99.73%)
**Survodutide** represents a significant advancement in **obesity** pharmacotherapy, offering a dual `glucagon receptor`-`GLP-1 receptor` agonism that appears to deliver greater weight loss than current `GLP-1R` mono-…
The emergence of **survodutide** as a potential dual `GLP-1R`/`glucagon receptor` agonist could significantly expand the therapeutic landscape for **obesity** and **MASH**. For individuals struggling with these interc…
A plain language review clarifies **survodutide's** dual-agonist mechanism and promising clinical performance for **obesity** and **liver disease**.
This phase 3 data positions survodutide as a highly promising therapeutic option for individuals with **obesity** and **MASLD**, potentially offering a dual benefit by addressing both conditions simultaneously. **The …
This Phase 3 trial is critical for establishing the efficacy and safety of **survodutide** specifically for Japanese adults with obesity, a population often underrepresented in global trials. **The results will provid…
Establishing bioequivalence between different drug formulations is crucial for drug development. It ensures that any changes in formulation (e.g., for improved stability, manufacturing, or patient convenience) do not …
Optimizing Survodutide's formulation is critical for its future development as a potential treatment for obesity and NASH. A formulation with improved bioavailability could lead to more effective dosing strategies, po…
The successful outcome of this Phase III trial could represent a significant advancement in the treatment of overweight and obesity, particularly for the Chinese population, where specific therapeutic options are high…
The successful completion of enrollment for this Phase III trial is a significant milestone in the development of new therapies for NASH and obesity. Given the limited treatment options for NASH, a condition affecting…
This Phase 1 study is crucial for the continued development of survodutide, as it provides foundational data on how the drug behaves in a specific ethnic population. Understanding the pharmacokinetics and safety profi…
Optimizing drug formulation is crucial for enhancing patient convenience, adherence, and ultimately, therapeutic efficacy for conditions like obesity and MASH. If Formulation B2 demonstrates superior or comparable bio…
Understanding the specific receptor binding profiles of BI 456906 is a critical first step in evaluating its potential as a novel therapeutic agent for obesity. If BI 456906 demonstrates significant and distinct gluca…
This Phase 1 study is critically important as it seeks to understand the fundamental metabolic mechanisms of survodutide, a novel therapeutic candidate for obesity. If survodutide demonstrates superior or distinct ben…
Establishing bioequivalence between different delivery devices for Survodutide is a critical step for its future clinical development and patient accessibility. If the pre-filled syringe and pen deliver the drug equiv…
If successful, this Phase 2 trial could represent a significant advancement in the treatment of chronic kidney disease, a condition with high morbidity and mortality. A drug that can effectively reduce albuminuria cou…
This large-scale Phase 3 trial is crucial for understanding the long-term cardiovascular impact of survodutide, a novel anti-obesity agent. A positive outcome would establish survodutide as a safe and effective treatm…
The successful outcome of this Phase III trial could represent a monumental step forward in treating MASH, a condition affecting millions globally with no current pharmacological cure. If Survodutide demonstrates sign…
Free, no account — handy when you're working with Survodutide.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account